This study examined the cost-effectiveness of adding a varicella vaccine to an existing childhood immunisation schedule relative to a counterfactual where the varicella vaccine is available on a user-pays basis (the current New Zealand situation).
The costs and consequences of chickenpox in an annual cohort of 57,200,15-month old children were simulated for a 30-year period.
The cohort simulation design captures the phasing-in'effects of routine varicella vaccination on the population.
From a health care payer's perspective (medical costs only) every dollar invested in a vaccination programme would return NZ $0.67.
However, from a societal point of view (which includes the value of work-loss), a vaccination programme would return NZ $2.79 for every dollar invested.
To implement a varicella vaccination programme covering 80% of 15-month old children in New Zealand would add more than NZ $1 million in net direct (health care) costs each year.
However, the indirect cost savings from reduced losses of work-time exceed NZ $2 million annually.
The net average health care cost per child vaccinated over the 30-year modelling period was $54 whereas the cost-savings from work-loss averted averaged $101 per child vaccinated.
Total cost-savings to society of $47 per child vaccinated, on average, could be gained from a vaccination programme. (...)
Mots-clés Pascal : Varicelle, Virose, Infection, Nourrisson, Homme, Prévention, Vaccination, Efficacité, Evaluation, Programme sanitaire, Analyse coût efficacité, Coût variable, Coût fixe, Economie santé, Nouvelle Zélande, Océanie, Epidémiologie
Mots-clés Pascal anglais : Varicella, Viral disease, Infection, Infant, Human, Prevention, Vaccination, Efficiency, Evaluation, Sanitary program, Cost efficiency analysis, Variable cost, Fixed cost, Health economy, New Zealand, Oceania, Epidemiology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0394181
Code Inist : 002B05C02B. Création : 22/03/2000.